Spark Therapeutics Leadership to Present at Three Upcoming Healthcare Investor Conferences

PHILADELPHIA, June 2, 2014 /PRNewswire/ -- Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company leadership will present at three healthcare investor meetings in June. 

• 2014 Jefferies Global Healthcare Conference, New York City, June 5
  Jeffrey D. Marrazzo, co-founder and CEO of Spark, will present on Spark's leadership in the advancement of potentially curative, one-time gene therapies.
• Jefferies Gene Therapy Summit, Boston, June 16
  Marrazzo will present on the company's expertise in ophthalmology.   
• Piper Jaffray GenomeRx Symposium, New York City, June 23
  Marrazzo will present along with Katherine A. High, M.D. and J. Fraser Wright, Ph.D., co-founders and scientific advisors to Spark. The three will participate in multiple panels, including discussions of genomic-based ophthalmologic treatments and regulatory needs in gene therapy clinical development.

About Spark Therapeutics, Inc.

Spark Therapeutics, Inc., is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies. Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark's founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. To learn more visit www.sparktx.com.  

For information contact:
Jessica Rowlands
Feinstein Kean Healthcare
202-729-4089
[email protected]

SOURCE Spark Therapeutics